Since Foxy-5 exhibits a unique anti-metastatic effect and since no toxic effects were detected in a recently completed phase 1 trial (www.clinicalTrials.gov; NCT02020291), we hypothesize that this peptide can be used in combination with presently used cytotoxic compounds and thus represents a new strategy for the treatment of prostate cancer patients with low expression of WNT5A. Here, WNT5A is linked to prostate carcinoma.